MedTrace Logo

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

NCT04721106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 188

Last updated 2026-02-10

No results posted yet for this study

Summary

Vizimpro will be approved for the treatment of EGFR NSLCL 1L in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Vizimpro after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Vizimpro will be observed.

Conditions

  • Lung Neoplasms

Interventions

DRUG

Vizimpro

treatment group

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-07
Primary Completion
2026-01-19
Completion
2026-01-19
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721106 on ClinicalTrials.gov